Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05953038

LSD Occupancy of the Serotonin 2A Receptor in the Human Brain

Lysergic Acid Diethylamide Occupancy of the Serotonin 2A Receptor in the Human Brain

Status
Active Not Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Rigshospitalet, Denmark · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using \[11C\]CIMBI-36 positron emission tomography.

Detailed description

Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive \[11C\]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.

Conditions

Interventions

TypeNameDescription
DRUGLysergic Acid Diethylamide TartrateD-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)

Timeline

Start date
2023-11-08
Primary completion
2027-12-18
Completion
2027-12-31
First posted
2023-07-19
Last updated
2024-12-18

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05953038. Inclusion in this directory is not an endorsement.